The Athenex team includes a deep bench of professionals with experience in pharmaceutical research, product development, manufacturing and quality assurance.

Li Shen, MBA, CPA

Vice President, Financial Planning & Treasury

Li has extensive experience in financial capital markets including 17 years of financial analysis, planning, accounting and auditing, asset management and risk management for both public and private companies. Prior to joining Athenex, Li worked in the audit and assurance services for PricewaterhouseCoopers in New York City, leading audit engagements in the capital market area. Her clients included key US banks, investment companies, the depository trust company and large insurance companies. She has a proven record of implementing procedures to promote financial excellence, optimizing company structure while serving as business partners to operational managers to improve financial results. Li graduated with an MBA in professional accounting from Rutgers University and she is a certified public accountant in New York State.

Prior to coming to the U.S., Li resided in Hangzhou, China working for a leading import and export company. Attending international expositions and travelling the world extensively, she has considerable experience with international business and trade.  She received her BA in English Language and Literature from Shanghai International Studies University.

E. Douglas Kramer, MD

Vice President, Clinical, Regulatory Affairs & Pharmacovigilance

Doug has over 20 years of experience in drug development, regulatory affairs and pharmaceutical risk management. He has been involved in successful approvals of treatments for addiction (including nicotine replacement and buprenorphine for opioid dependence), opioid analgesics, and IV Temodar for glioblastoma. His work has included international drug regulatory issues and strategy and development of risk management plans for post marketing drug safety. Doug holds a Doctor of Medicine (MD) degree from Columbia University and a Bachelor of Arts degree in Chemistry from Vassar College.

John Matthei

Vice President, Human Resources

John has over 20 years of global human resources and operations management experience in the healthcare industry with a concentration in developing human resource competencies in high growth businesses. In his role at Athenex, John is responsible for providing overall leadership to the company’s global human resources organization and programs, including leadership and organization development, performance management, training, compensation and benefits, staffing, employee relations, HRIS, and affirmative action/diversity.

Prior to joining Athenex, John held several leadership roles including Vice President, Human Resources for Sagent Pharmaceuticals, Vice President of Human Resources at Pfingsten Partners, Global Human Resource, Executive Vice President for Stericycle, and varying positions of management responsibility in Human Resources at Baxter Healthcare.

John attended Loyola University of Chicago and holds a B.A. in Organizational Communications, as well as several executive educational certificates in operations from Kellogg School of Management.

Michael Smolinski, PhD

Vice President, Preclinical Operations

As the Company’s primary chemist since 2008, Michael has contributed substantially to the development of Athenex’s clinical pipeline, operations, and platform technologies, including the Optimized PhotoAffinity Labelling (OPAL) platform technology which is a keystone to Athenex’s drug discovery efforts today.  He has made significant contributions to Athenex’s clinical pipeline through hands-on research and management of IND-enabling studies including many aspects of drug substance, product, and process development.

Prior to joining Athenex, Michael completed a postdoctoral position at Scripps Florida where he focused on the drug discovery of kinase inhibitors, which resulted in several patent applications and publications.  Michael obtained his PhD from SUNY University at Buffalo, and his multi-disciplinary PhD thesis on the “Thermodynamics of Molecular Recognition” contained breakthrough findings for the biotechnology industry.

Robert F. Keem

Vice President, NY Technical Operations

Rob, an analytical chemist, has implemented effective quality management systems for over 20 years. Prior to joining Athenex, in his role as Global Quality Leader for Thermo Fisher Scientific, Rob oversaw 13 regulated manufacturing sites around the world. He has extensive experience in Quality Assurance and Validation, having led large teams in pharma, biotech and medical device companies, including Bristol Myers Squibb and Fujisawa, and assuming roles in R&D, Project Management, QC and QA/QC. Rob is proficient in execution of compliance to GMP 21 CFR 210/211/820 and has experience with lean manufacturing, six sigma training, and risk management. Early in his career, Rob focused on method development and quality control testing for biomedical companies. He received a Bachelors in Chemistry and a Master in Analytical Chemistry from Buffalo State College, State University of New York.

Jacqueline Li

Director, Corporate Development & Investor Relations
CFO, Axis Therapeutics

Jacqueline joined Athenex in 2017 to support the company’s strategic and operational objectives, including in respect of capital raising, business development, investor relations and project management. Jacqueline is also the CFO of Axis Therapeutics, a majority-owned subsidiary of Athenex principally engaged in the development of T cell therapies. Prior to joining Athenex, Jacqueline was with Credit Suisse’s Investment Banking and Capital Markets division in Hong Kong, advising clients from various sectors spanning life sciences, general industrials, internet and others. Over the past 10 years, Jacqueline has developed deep experience through the execution of capital markets, mergers and acquisitions, strategic partnership and other financing transactions, including the initial public offering of Athenex. Jacqueline graduated with a B.S. in Economics from The Wharton School, University of Pennsylvania.

Ben Tang, MS

Business Advisor and Executive Assistant to the CEO

Ben Tang is a venture capitalist with more than 10 years of experience in direct investment, corporate finance and venture capital in China and US. At Mandra Capital, he is responsible for managing a portfolio of private company investments in the life science, technology and internet space from incubation to growth stage with successful track records in following-on financings and exit events, where he is heavily involved in their financing and strategic operation activities. In addition to his responsibilities at Mandra, Ben is currently a member of the IP Assessment Committee at Hong Kong Polytechnic University, and a director of a number of private companies including Aurora Limited (big data analytics), Shicai Online (on-demand ingredients delivery), Jimutour (Chinese overseas travel platform) and (coding social platform). Prior to joining Mandra, Ben was an investment analyst with KGR Capital (now LGT Capital Partners) based in Hong Kong. Ben holds a Masters degree in engineering from Stanford University.

Raymond Yeung MBA, MSc, BSc (Econ), FIBMS

Senior Director and Deputy Head, Clinical Research & Regulatory Affairs – Asia-Pacific Athenex (Hong Kong)

Raymond has over 30 years of experience in the pharmaceutical and healthcare industries, holding senior positions in Preclinical & Clinical CROs, GMP manufacturing facilities, as well as hospital and community medical laboratories. In his previous role as General Manager of Fortune Pharmacal in Hong Kong, Raymond oversaw all aspects of GMP Manufacturing, Quality Assurance, Quality Control, Plant Engineering, Sales & Marketing, as well as warehousing and distribution.  Fortune Pharmacal is one of the largest and most advanced GMP plants in Hong Kong. Previously, Raymond was the Managing Director of AMRI (Albany Molecular Research Inc. USA)’s Singapore operation. AMRI Singapore is one of the largest chemistry-focused preclinical CRO in South East Asia, specializing in Medicinal Chemistry and other early Drug Discovery services. Prior to AMRI, Raymond worked for MDS Pharma Services as its Director (Asia Pacific) in Singapore, supervising the operations of Central Laboratories, Centralized ECG services, and Clinical Development. MDS Pharma Services was one of the major global Contract Research and Contract Manufacturing Organizations during the first decade of this century. Raymond’s expertise includes GCP, GLP, GMP Pharmaceutical Manufacturing, Central Laboratories, Clinical Trials, Preclinical studies, Microbiology, and Clinical Pathology Laboratory Services.

Raymond holds an MBA from the State University of California at Hayward (now East Bay) and an MSc in Medical Microbiology from the University of the West of England at Bristol, UK.  Raymond is also a BSc (Econ) graduate from the University of London, and he is currently a Fellow of the Institute of Biomedical Sciences of the United Kingdom.

Xiaodong Wang, MBA

General Manager – Chongqing Taihao Pharmaceutical

Xiaodong has served as General Manager of Chongqing Taihao Pharmaceutical since August 2012. He participated in the establishment, development, and restructuring of the Chongqing Taihao Pharmaceutical from 2004 to 2012, and served as Vice President of Supply, Marketing and Sales. Xiaodong served as Manager of Administration, Marketing and Sales of Chongqing United Pharmaceutical, later merged to Holley Pharmaceutical (SSE: 600607) from 1997 to 2004. He has over 18 years experience in pharmaceutical and chemistry.

Xiaodong has his MBA from Chongqing University in China.

Xiaoli Yu, MBA

Chief Financial Officer – Chongqing Taihao Pharmaceutical

Xiaoli has served as Chongqing Taihao Pharmaceutical’s Vice General Manager of administration and Chief Financial Officer since August 2012. Xiaoli served in Chongqing Xiyong Microelectronics Industrial Park, a Chongqing Municipal key state-owned enterprises, engaged in the establishment of finance department from 2011 to 2012. She served as Audit Manager, CFO of Chongqing Holley Pharmaceutical, which is a listed pharmaceutical company in China (SSE: 600607) and has more than 20 domestic and overseas subsidiaries, from August 2004 to October 2011. Xiaoli served as Audit, Project Evaluation Manager of Chongqing Kanghua Accounting Firm from January 2000 to July 2004.

Xiaoli held various certificates, such as CPA, Certified Real Estate Appraiser in China. She also has her MBA from Chongqing University.

Edward Chan, CPA

Chief Financial Officer – Comprehensive Drug Enterprises

Edward has over 15 years of experience in accounting, auditing, financial management, corporate finance and risk management. Prior to joining Athenex, Edward was the Financial Controller of Hong Kong listed companies. Prior to that, Edward was a Finance Manager of a US listed energy company and an audit manager of KPMG Hong Kong.

Edward graduated with a Bachelor of Business Administration major in professional accounting and he is also a member of The Hong Kong Institute of Certified Public Accountant.